注:本文所涉Rixubis产品尚未在中国上市。

[1]20th Anniversary Report on the Annual Global Survey 2018. World Federation of Hemophilia. Available at: Last accessed May 2020.

[2]Iorio, A., et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019 Oct 15;171(8):540-546.

[3]WFH 2020 Virtual Summit. Abstract MED‐FP‐005 (363). Effectiveness, safety, and health‐related quality of life outcomes in patients with hemophilia A receiving antihemophilic factor (recombinant) in a real‐world setting: results of a 6‐year interim analysis of the AHEAD International study.

[4]WFH 2020 Virtual Summit. iPoster MTD-PO-057. Multi-department collaboration for the management of hemophilia A: a physician survey in China.

[5]WFH 2020 Virtual Summit. iPoster MED-PO-018. Safety and Effectiveness of Rixubis in Patients with Hemophilia B in South Korea: A Real-World, Prospective, Post-marketing Surveillance Study.

文章来源：《中国实验血液学杂志》 网址: http://www.zgsyxyxzz.cn/zonghexinwen/2020/1030/470.html